Share this video  

ESMO 2023 | Utilizing antibody-drug conjugates in the treatment of metastatic urothelial carcinoma

Arlene O. Siefker-Radtke, MD, MD Anderson Cancer Center, Houston, TX, discusses the use of antibody-drug conjugates in the treatment of metastatic urothelial carcinoma, elaborating on the possible combination of these immunotherapies in clinical practice to improve treatment outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.